These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18310583)

  • 21. Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study.
    Kongsakon R; Papadopoulos KI; Saguansiritham R
    Int Clin Psychopharmacol; 2005 Sep; 20(5):253-6. PubMed ID: 16096515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.
    Gambi F; De Berardis D; Campanella D; Carano A; Sepede G; Salini G; Mezzano D; Cicconetti A; Penna L; Salerno RM; Ferro FM
    J Psychopharmacol; 2005 Sep; 19(5):483-7. PubMed ID: 16166185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.
    Cho SJ; Yook K; Kim B; Choi TK; Lee KS; Kim YW; Lee JE; Suh S; Yook KH; Lee SH
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):208-11. PubMed ID: 21095214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of mirtazapine in post-traumatic stress disorder.
    Connor KM; Davidson JR; Weisler RH; Ahearn E
    Int Clin Psychopharmacol; 1999 Jan; 14(1):29-31. PubMed ID: 10221639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study.
    Ng CG; Boks MP; Roes KC; Zainal NZ; Sulaiman AH; Tan SB; de Wit NJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):491-8. PubMed ID: 24503279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mirtazapine for treatment-resistant depression: a preliminary report.
    Wan DD; Kundhur D; Solomons K; Yatham LN; Lam RW
    J Psychiatry Neurosci; 2003 Jan; 28(1):55-9. PubMed ID: 12587851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania.
    Danileviciūte V; Sveikata A; Adomaitiene V; Gumbrevicius G; Fokas V; Sveikatiene R
    Medicina (Kaunas); 2009; 45(10):778-84. PubMed ID: 19996664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder.
    Smith WT; Glaudin V; Panagides J; Gilvary E
    Psychopharmacol Bull; 1990; 26(2):191-6. PubMed ID: 2236455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.
    Honig A; Kuyper AM; Schene AH; van Melle JP; de Jonge P; Tulner DM; Schins A; Crijns HJ; Kuijpers PM; Vossen H; Lousberg R; Ormel J;
    Psychosom Med; 2007; 69(7):606-13. PubMed ID: 17846258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study.
    Muehlbacher M; Nickel MK; Nickel C; Kettler C; Lahmann C; Pedrosa Gil F; Leiberich PK; Rother N; Bachler E; Fartacek R; Kaplan P; Tritt K; Mitterlehner F; Anvar J; Rother WK; Loew TH; Egger C
    J Clin Psychopharmacol; 2005 Dec; 25(6):580-3. PubMed ID: 16282842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of mirtazapine versus placebo on alcohol consumption in male high consumers of alcohol: a randomized, controlled trial.
    de Bejczy A; Söderpalm B
    J Clin Psychopharmacol; 2015 Feb; 35(1):43-50. PubMed ID: 25517204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial.
    Terevnikov V; Stenberg JH; Joffe M; Tiihonen J; Burkin M; Tchoukhine E; Joffe G
    Hum Psychopharmacol; 2010 Aug; 25(6):431-8. PubMed ID: 20737516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial.
    Terevnikov V; Stenberg JH; Tiihonen J; Chukhin E; Joffe M; Burkin M; Joffe G
    Int J Neuropsychopharmacol; 2013 Aug; 16(7):1661-6. PubMed ID: 23217660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression.
    Ueno F; Nakajima S; Suzuki T; Abe T; Sato Y; Mimura M; Uchida H
    J Clin Psychiatry; 2015 Apr; 76(4):434-9. PubMed ID: 25919835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia.
    Stenberg JH; Terevnikov V; Joffe M; Tiihonen J; Tchoukhine E; Burkin M; Joffe G
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1080-6. PubMed ID: 21402120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study.
    Haapasalo-Pesu KM; Vuola T; Lahelma L; Marttunen M
    J Child Adolesc Psychopharmacol; 2004; 14(2):175-84. PubMed ID: 15319015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mirtazapine in inpatient treatment of depressed patients].
    Bailer U; Praschak-Rieder N; Pezawas L; Kasper S
    Wien Klin Wochenschr; 1998 Oct; 110(18):646-50. PubMed ID: 9816638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.